Barcelona

• Clinical Trial of Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas Ended recruitment
  2024-511987-10-00 4 2025-04-07 Selected Advanced Soft-Tissue Sarcomas
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A clinical study of raludotatug deruxtecan in people with gastrointestinal cancers (MK-5909-005) Ended recruitment
  2024-517416-30-00 10 2025-03-31 Gastrointestinal Cancers
• A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced … Ended recruitment
  2022-501483-18-00 10 2025-03-28 Advanced Non-Small Cell Lung Cancer
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF PF-06939926 IN DMD Ended recruitment
  2023-508510-42-00 5 2025-03-24 DUCHENNE MUSCULAR DYSTROPHY (DMD)
• A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (anti­IL­33 mAb) in participants with chronic rhinosi … Ended recruitment
  2024-515576-12-00 4 2025-03-20 Respiratory tract diseases
• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended recruitment
  2024-514133-38-00 5 2025-03-19 Ocular Myasthenia Gravis
• A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended recruitment
  2024-513738-39-00 9 2025-03-18 IDH1-mutant Glioma
• CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult … Ended recruitment
  2024-516247-62-00 5 2025-03-10 Hereditary Angioedema
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) in Pancreatic Exocrine Insufficiency (PEI) due to gastrectomy. Ended recruitment
  2023-507837-18-00 6 2025-03-06 Male and female patients aged ≥ 18 to ≤ 80 after total gastrectomy.
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended recruitment
  2024-512946-41-00 5 2025-03-05 Menstrual Migraine
• A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration … Ended recruitment
  2024-515022-88-00 5 2025-03-03 Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
• BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney … Ended recruitment
  2023-503337-21-00 4 2025-02-28 Prophylaxis of Renal Allograft Rejection
• AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protoco … Ended recruitment
  2024-511253-21-00 3 2025-02-28 Thoracic tumors with homozygous MTAP-deletion
• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended recruitment
  2024-515089-15-00 5 2025-02-28 active non-infectious uveitis (intermediate uveitis, posterior uveitis
• A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni … Ended recruitment
  2024-513970-23-00 4 2025-02-27 Previously Untreated Chronic Lymphocytic Leukemia
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants … Ended recruitment
  2024-511287-85-00 5 2025-02-17 Cholestatic Pruritus
• Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) Ended recruitment
  2024-513384-15-00 4 2025-02-13 Parkinson’s disease
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518343-38-00 5 2025-02-12 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• FINESSE: Research on improving albuminuria in patients with chronic kidney disease through the use of finerenone and semaglutide. Ended recruitment
  2023-506434-69-00 4 2025-02-11 Chronic Kidney Disease

Showing 1,705–1,728 of 3,391 trials